Business

Adagio Medical to Present at the Piper Sandler 37th Annual Healthcare Conference

LAGUNA HILLS, Calif., November 05, 2025--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025, at 10:30 a.m. ET at the Lotte Palace in New York, NY.

articleAdagio Medical Holdings, IncNovember 5, 20251/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-present-piper-sandler-130000096
Adagio Medical to Present at the Piper Sandler 37th Annual Healthcare Conference

About this update from Adagio Medical Holdings, Inc

[{"type":"text","content":"LAGUNA HILLS, Calif., November 05, 2025--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025, at 10:30 a.m. ET at the Lotte Palace in New York, NY.","length":439,"tagName":"p"},{"type":"text","content":"Presentation InformationA live and recorded webcast of the presentation will be available at:https://event.webcasts.com/starthere.jsp?ei=1742138&tp_key=f2a06e9abc","length":168,"tagName":"p"},{"type":"text","content":"About Adagio Medical Holdings, Inc.","length":35,"tagName":"p"},{"type":"text","content":"Adagio is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Cryoablation (ULTC) technology. ULTC is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The Company is currently focused on the treatment of ventricular arrhythmias with its purpose-built vCLAS™ Cryoablation System, which is CE Marked and is currently under evaluation in the Company’s FULCRUM-VT U.S. IDE Pivotal Study.","length":585,"tagName":"p"},{"type":"text","content":"View source version on businesswire.com: https://www.businesswire.com/news/home/20251105837821/en/","length":98,"tagName":"p"},{"type":"text","content":"Contacts","length":8,"tagName":"p"},{"type":"text","content":"Debbie KasterChief Financial Officer and Chief Business [email protected]","length":90,"tagName":"p"}]

More updates from Adagio Medical Holdings, Inc

cardiac arrhythmiascatheter ablationHealthcare ConferenceBUSINESS WIREThe Company